Photo of Benjamin William Perry

Ben Perry’s practice spans the spectrum of legal services. On the litigation side, Ben represents clients at the trial and appellate level against a wide variety of claims in state and federal courts. His practice primarily concentrates on complex civil litigation, products liability defense, and representing financial institutions and mortgage companies in civil litigation. As part of the Banking and Financial Services Practice Group, he defends mortgage servicers, investors, and related entities against numerous state and federal law claims arising out of lending and loan servicing practices, including alleged violations of the Telephone Consumer Protection Act (TCPA) and various claims relating to the sale of bank-owned real estate. Ben also has substantial experience defending banks and investors in hundreds of cases related to homeowner’s association (HOA) superpriority liens, and he has represented a company’s founder and CEO facing claims brought by the SEC for alleged embezzlement of company funds.

Delta-8-tetrahydrocannabinol (Δ8-THC) is legal under federal law. Or is it? It depends on who you ask.

The Ninth Circuit has now weighed in on the issue, following the lead of several states, to conclude that Δ8-THC products are federally legal under the Agriculture Improvement Act of 2018 (the 2018 Farm Bill). But the Ninth

The stratospheric rise of products containing ∆8-tetrahydrocannabinol (Delta-8 THC) and ∆10-tetrahydrocannabinol (Delta-10 THC), both of which can cause psychoactive effects similar to ∆9-THC (the substance codified as “marihuana” by the federal Controlled Substances Act), have raised questions regarding these products’ legality under federal and state law. Recent litigation developments have indicated a possible trend toward

Cannabis operators (from marijuana to hemp-derived products such as CBD) often get the sense they are one of the central targets of the federal government’s reach. But they are not in the same league lately as the COVID-19 virus. Earlier this month, those worlds collided.

The U.S. Food and Drug Administration (FDA) and the Federal